Asian Journal of Pharmaceutical Sciences · 2020 · 27 citations · 47 references
PharmacyImmunologyOncologyDrug DeliveryImmunotherapyNanobiotechnologyCancer NanomedicineCancer VaccinesNanomedicineNanoparticle FormulationsVaccine DeliveryVaccine PlatformsBiomimetic Vaccine CarriersNanocarriersNanoparticle Vaccine DeliveryNanoparticle Vaccine PlatformsNanovaccinesProphylactic VaccinesT Cell Response InductionT-cell Responses To Tumor Antigens
Currently, the cancer immunotherapy has made great progress while antitumor vaccine attracts substantial attention. Still, the selection of adjuvants as well as antigens are always the most crucial issues for better vaccination. In this study, we proposed a biomimetic antitumor nanovaccine based on biocompatible nanocarriers and tumor cell membrane antigens. Briefly, endogenous calcium pyrophosphate nanogranules with possible immune potentiating effect are designed and engineered, both as delivery vehicles and adjuvants. Then, these nanocarriers are coated with lipids and B16-OVA tumor cell membranes, so the biomembrane proteins can serve as tumor-specific antigens. It was found that calcium pyrophosphate nanogranules themselves were compatible and possessed adjuvant effect, while membrane proteins including tumor associated antigen were transferred onto the nanocarriers. It was demonstrated that such a biomimetic nanovaccine could be well endocytosed by dendritic cells, promote their maturation and antigen-presentation, facilitate lymph retention, and trigger obvious immune response. It was confirmed that the biomimetic vaccine could induce strong T-cell response, exhibit excellent tumor therapy and prophylactic effects, and simultaneously possess nice biocompatibility. In general, the present investigation might provide insights for the further design and application of antitumor vaccines.
47
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott, Zhuting Hu, Derin B. Keskin et al. · Nature · 2017 · 2.9K citations
Medicine, Immunology, Oncology +12
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Uğur Şahin, Evelyna Derhovanessian, Matthias Miller et al. · Nature · 2017 · 2.5K citations
Medicine, Immunology, Oncology +14
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Ronnie H. Fang, Che‐Ming Jack Hu, Brian T. Luk et al. · Nano Letters · 2014 · 1.5K citations · Full text
Pharmacy, Immunology, Pharmaceutics +17